Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care

AIM: Due to extensive treatment switching in the MAVORIC trial, lack of UK regulatory licence for the comparator, overall survival (OS) with mogamulizumab was compared with patients with previously treated advanced mycosis fungoides/Sézary syndrome (MF/SS) in real-world setting. DESIGN, SETTING &...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkins, Neil, Muszbek, Noemi, Evans, Rachel, McNamara, Linda, Jones, Trefor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690402/
https://www.ncbi.nlm.nih.gov/pubmed/37642410
http://dx.doi.org/10.57264/cer-2023-0017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690402/
https://www.ncbi.nlm.nih.gov/pubmed/37642410
http://dx.doi.org/10.57264/cer-2023-0017

Ejemplares similares